1. Introduction {#j_med-2017-0058_s_001}
===============

Myasthenia gravis is an autoimmune disorder induced by neurotransmission defects at the neuromuscular junction, which is characterized by muscle weakness and fatigue. It has been well-documented that approximately 10-15% of MG patients also suffer from thymoma, and nearly all these patients have detectable AchR antibodies and generalized disease \[[@j_med-2017-0058_ref_001]\]. Approximately 30% of patients with thymoma develop MG, and even more have AchR antibodies without MG \[[@j_med-2017-0058_ref_002]\]. Thymectomy has been recommended for MG patients with thymoma, which could not only reduce the risk of proliferation and invasion, but also improve MG symptoms for most patients \[[@j_med-2017-0058_ref_003]\]. For patients either not responding to thymectomy or suffering from MG recurrence post thymectomy, corticosteroids are the most commonly used and most effective immunosuppressive treatments.

Corticosteroids are the first line treatment of mild to moderate MG, and have been considered to be the standard therapy currently. Though MG patients could do well and have well-controlled disease with corticosteroid, either alone or combined with other immunosuppressive agents \[[@j_med-2017-0058_ref_004]\], most need long-term and even life-long treatment with low-dose steroids treatment. Long-term steroids use will increase the appetite of patients, which increases the risks of central obesity, glucose intolerance and hypertension \[[@j_med-2017-0058_ref_001],[@j_med-2017-0058_ref_003]\].

As the prevalence of hypertension and diabetes globally increases \[[@j_med-2017-0058_ref_005],[@j_med-2017-0058_ref_006]\], the number of thymoma-associated MG patients accompanied by hypertension and/or diabetes is inevitably growing. The presence of hypertension/ diabetes poses an additional burden to a patient with myasthenia gravis. Though hypertension and/or diabetes is not absolute contraindication to steroids, long-term use of steroids would definitely increase the difficulty on the control of blood pressure and/or glucose as hyperglycemia and hypertension are the major side effects of long-term steroids use. This would lead to additional medication in order to control blood pressure/glucose, which increases the treatment cost for patients. Moreover, it also potentially increases the risk of cardiovascular diseases-related death \[[@j_med-2017-0058_ref_005]\], considering that diabetes and hypertension are major predisposing factors. Thus, other therapeutic options for this group of patients are of great clinical importance.

Based on the clinical experiences at our center since 2005, we have observed favorable responses of MG after docetaxel/cisplatin therapy for thymoma-associated MG patients. Even in MG patients with unresectable metastatic thymoma, the MG symptoms could be significantly improved after docetaxel plus cisplatin therapy \[[@j_med-2017-0058_ref_007]\]. In the present study, we report the therapeutic effects and adverse events of docetaxel plus cisplatin therapy in a serial of thymoma-associated MG patients complicated with hypertension and/or diabetes who did not respond to thymectomy or suffered from MG recurrence post thymectomy.

2. Subjects and methods {#j_med-2017-0058_s_002}
=======================

During the period between January 2014 and June 2015, 9 patients with thymoma-associated MG complicated with hypertension and/or diabetes, either not responding to thymectomy or suffering from MG recurrence, underwent docetaxel plus cisplatin treatment at the Myasthenia Gravis Treatment Center of Hebei Province, First Hospital of Shijiazhuang (Hebei, China). The study was approved by the Ethical Committee of the First Hospital of Shijiazhuang, and informed consent was obtained from all the 9 patients.

Thymoma was diagnosed *via* computed tomography (CT) scan, and histological confirmation was done based on the World Health Organization (WHO) histological classification of thymoma \[[@j_med-2017-0058_ref_008]\]. The clinical and pathologic staging of thymoma was done according to the Masaoka's staging system \[[@j_med-2017-0058_ref_009]\]. The diagnose of MG was based on the clinical symptoms and other examinations including methyl sulfate neostigmine test, electromyography, and serum antibody tests \[[@j_med-2017-0058_ref_010]\]. The severity and classification of MG were assessed in accordance with modified Osserman scale \[[@j_med-2017-0058_ref_011]\]. Prior to the docetaxel and cisplatin treatment, all patients received surgical resection of thymoma (7 with thoracotomy; 2 with minimally invasive thoracoscopic thymectomy). MG symptoms were not alleviated in 4 patients, and MG recurrence occurred in the other 5 patients. The longest MG course was 96 months, with the median of 18 months. The relative information of medication on blood pressure and/or glucose control in all patients has been provided in [Table 1](#j_med-2017-0058_tab_001){ref-type="table"}.

###### 

Characteristics of patients before docetaxel/cisplatin treatment.

  Patient \#                             \#1          \#2                                                                 \#3       \#4                   \#5                                \#6                      \#7                  \#8                \#9
  -------------------------------------- ------------ ------------------------------------------------------------------- --------- --------------------- ---------------------------------- ------------------------ -------------------- ------------------ ------------------------------------
  Age/Sex                                63 F         57 F                                                                41 M      66 M                  52 M                               77 M                     72 F                 59 M               50 M
  Duration of MG (months prior)          12 mos       18 mos                                                              72 mos    96 mos                24 mos                             60 mos                   10 mos               3 mos              5 mos
  MG severity (Before treatment)         II B         II B                                                                II B      II B                  II B                               II B                     II B                 I                  II B
  Thymoma                                                                                                                                                                                                                                                     
  Masaoka stage                          II           III                                                                 I         I                     II                                 II                       I                    I                  II
  WHO type                               B3           B2/B3                                                               B1        B3                    B3                                 B2                       B2                   B2                 B2
  Thymectomy (months prior)              18 mos       1 mo                                                                50 mos    1 mo                  7 mos                              55 mos                   4 mos                1 mo               1 mo
  Diabetes                               \\           \\                                                                  Type 2    \\                    \\                                 Type 2                   Type 2               \\                 \\
  Medication for DM                      \\           \\                                                                  insulin   \\                    \\                                 Acarbose glibenclamide   insulin              \\                 \\
  Hypertension                           Stage 3      Stage 2                                                             \\        Stage 3               Stage 3                            \\                       Stage 3              Stage 3            Stage 2
  Medication for Hypertension            Metoprolol   Kato Pury Nifedipine                                                \\        Nifedipine            Irbesartan Felodipine Metoprolol   \\                       Nifedipine Betaloc   Adalat Valsartan   Metoprolol Enalapril Nitrendipines
  Additional features before treatment                Chronic hepatitis C; pressure ulcers; right lower limb amputation             Parkinson's disease                                                                                    Gout               
  AchR antibody before treatment         7.62         6.92                                                                13.99     8.69                  8.53                               11.19                    13.43                9.97               7.38

Severity of MG is rated according to modified Osserman classification.

MG, myasthenia gravis; WHO: World Health Organization.

All patients were treated with 75 mg/m^2^ of docetaxel and 70 mg/m^2^ of cisplatin on day 1, and the treatment could be repeated at 3-week intervals \[[@j_med-2017-0058_ref_007],[@j_med-2017-0058_ref_012],[@j_med-2017-0058_ref_013],[@j_med-2017-0058_ref_014]\]. The treatment ranged from 1 to 4 cycles, according to the status of the patients. Therapeutic effects of docetaxel/cisplatin on MG symtoms were evaluated based on the clinical relative scoring (CRS) system in China as described previously \[[@j_med-2017-0058_ref_015],[@j_med-2017-0058_ref_016]\]. Adverse effects during the treatment were evaluated in accordance with the World Health Organization criteria.

3. Results {#j_med-2017-0058_s_003}
==========

Among the 9 thymoma-associated MG patients, 2 were complicated with type 2 diabetes, 6 with hypertension, and 1 with both diabetes and hypertension. The median age was 59 years, ranging from 41 to 77 years. The characteristics of each patient were shown in [Table 1](#j_med-2017-0058_tab_001){ref-type="table"}. Previously, all patients underwent surgical resection of thymoma (7 with thoracotomy; 2 with minimally invasive thoracoscopic thymectomy). MG symptoms did not alleviated in 4 patients, and the other 5 suffered from MG recurrence. The median course of MG was 18 months, ranging from 9 to 96 months. Before the docetaxel/cisplatin therapy, 8 patients were stage IIB, and the remaining 1 patient were stage I according to the Osserman classification. The median time from thymectomy to docetaxel/cisplain therapy was 4 months, ranging from one to 55 months.

The cycle of docetaxel/cisplatin treatment ranged from 1 to 4 (median, 2 cycles), as shown in [Table 2](#j_med-2017-0058_tab_002){ref-type="table"}. One patient also received radiotherapy (\#3), and 1 patient underwent 2 courses of plasmapheresis (\#4). After docetaxel/cisplain therapy, the clinical symptoms of MG were significantly improved in all patients, including 2 patients with complete remission (CRS ≥ 95%), 3 with basic remission (80% ≤ CRS \< 95%), 3 with marked improvement (50% ≤ CRS \< 80%), and 1 with improvement (25% ≤ CRS \< 50%). The levels of serum AChR antibodies (AchR-Ab) were reduced in 8 patients; while slight increase was observed in 1 patient (\#2) ([Table 3](#j_med-2017-0058_tab_003){ref-type="table"}). The patients were followed up to 29 months, with a median duration of 18 months. MG recurrence occurred in patient \#3 one year after docetaxel/cisplain therapy. No influence of chemotherapy on blood pressure/glucose has been observed, and all patients maintained previous treatment protocols on blood pressure/glucose control. Minor adverse effects were observed in only 2 patients, including 1 patient with Grade II gastrointestinal reaction (\#2), and the other with pulmonary infection (\#3).

###### 

Outcome of patients after docetaxel plus cisplatin therapy.

  Patient [^\#^](#j_med-2017-0058_fn_001){ref-type="table-fn"}         [^\#^](#j_med-2017-0058_fn_001){ref-type="table-fn"}1   [^\#^](#j_med-2017-0058_fn_001){ref-type="table-fn"}2   [^\#^](#j_med-2017-0058_fn_001){ref-type="table-fn"}3   [^\#^](#j_med-2017-0058_fn_001){ref-type="table-fn"}4   [^\#^](#j_med-2017-0058_fn_001){ref-type="table-fn"}5   [^\#^](#j_med-2017-0058_fn_001){ref-type="table-fn"}6   [^\#^](#j_med-2017-0058_fn_001){ref-type="table-fn"}7   [^\#^](#j_med-2017-0058_fn_001){ref-type="table-fn"}8   [^\#^](#j_med-2017-0058_fn_001){ref-type="table-fn"}9
  -------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  Docetaxel/cisplatin (cycle)                                          1                                                       2                                                       2                                                       2                                                       4                                                       3                                                       1                                                       2                                                       3
  Other treatments                                                                                                                                                                     RT                                                      PP                                                                                                                                                                                                                                                                                      
  CRS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Before                                                               10                                                      26                                                      15                                                      4                                                       21                                                      10                                                      10                                                      9                                                       19
  After                                                                0                                                       8                                                       2                                                       0                                                       4                                                       5                                                       6                                                       2                                                       2
  Blood pressure[^\*^](#j_med-2017-0058_fn_011){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Before                                                               118/87                                                  135/75                                                  139/92                                                  120/80                                                  154/97                                                  130/60                                                  136/78                                                  143/88                                                  132/101
  After                                                                \\                                                      97/62                                                   134/70                                                  120/80                                                  126/83                                                  130/60                                                  137/70                                                  138/90                                                  127/71
  Blood glucose[^\#^](#j_med-2017-0058_fn_001){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Before                                                               4.3                                                     6.4                                                     18.3                                                    7.2                                                     4                                                       5                                                       7.8                                                     5.4                                                     5.8
  After                                                                \\                                                      6.1                                                     13.6                                                    6.2                                                     4                                                       7.2                                                     6.4                                                     5.4                                                     3.4
  MG response                                                          CR                                                      MI                                                      BR                                                      CR                                                      BR                                                      MI                                                      IM                                                      MI                                                      BR
  Adverse effects                                                                                                              Grade II gastrointestinal reaction                      Pulmonary infection                                                                                                                                                                                                                                                                                                                             
  Follow up (Months)                                                   28                                                      11                                                      14                                                      22                                                      29                                                      23                                                      15                                                      14                                                      18

RT, radiotherapy; PP, plasmapheresis; CRS, clinical relative score; MG, myasthenia gravis; AchR-Ab, Antiacetylcholine receptor antibodies; CR, Complete remission; BR, basic remission; MI, Marked improvement; IM, improvement.

Blood glucose in patients with diabetes is detected with relative medication for DM

Blood pressure in patients with hypertension is detected under daily antihypertensive medication

###### 

Change in AchR-Ab levels.

  Patient \#   Pre-docetaxel/cisplatin   Post docetaxel/cisplatin
  ------------ ------------------------- --------------------------
  \#1          7.62                      0.55
  \#2          6.92                      7.66
  \#3          13.99                     10.5
  \#4          8.69                      4.54
  \#5          8.53                      7.28
  \#6          11.19                     10.57
  \#7          13.43                     2.72
  \#8          9.97                      1.8
  \#9          7.38                      7.29

AchR-Ab, Antiacetylcholine receptor antibodies.

4. Discussion {#j_med-2017-0058_s_004}
=============

In the present study, we revealed that 9 thymoma-associated MG patients complicated with hypertension and/or diabetes had favorable responses to docetaxel plus cisplatin therapy. Previously, these patients did not respond to thymectomy or suffered from MG recurrence post thymectomy. The median number of docetaxel/cisplatin treatment cycle was only 2, ranging from 1 to 4. After treatment, 8 out of the 9 (88.9%) patients were achieved at least marked improvement, with 2 patients achieved complete remission. Minor adverse effects were observed in only 2 patients, including 1 patient with Grade II gastrointestinal reaction, and the other with pulmonary infection.

Conventional immunosuppressive treatment has been the first-line therapy for adult MG patients, and longterm and even life-long treatment with low-dose steroids is required for most patients. It has been reported that MG patients with corticosteroids treatment had a 1.46-fold increased risk of developing diabetes mellitus as compared with non-MG cohort; while those without corticosteroids had no increase risk of DM \[[@j_med-2017-0058_ref_017]\]. In our study, we found that docetaxel/cisplatin treatment did not influence the medication for hypertension/DM.

Systematic chemotherapy with docetaxel and cisplatin has been used as one of the most common regimens in patients with thymic carcinoma \[[@j_med-2017-0058_ref_018]\]. We have used this regimen in patients with thymic carcinoma back to 2005. Interestingly, we have found that the responses of thymic carcinoma were minor to moderate, but the symptoms of MG were markedly improved by this regimen. Even in MG patients with unresectable metastatic thymoma, the symptom of MG could be markedly improved after docetaxel/cisplatin therapy \[[@j_med-2017-0058_ref_007]\]. Thus far, docetaxel/cisplatin therapy has proved to be generally safe and well tolerated in MG patients with thymoma, based on the observations at our center since 2005. Of the 9 patients treated at our center, almost half of patients (n=4, 44.4%) only received 2 cycles of docetaxel/cisplatin treatment. Over the long run, docetaxel/cisplatin treatment may avoid certain stress in control of bodyweight, blood pressure and blood glucose of long-term treatment with low-dose immunosuppression, with relative short period of treatment. This would especially benefit MG patients complicated with diabetes and/or hypertension.

All these patients have returned to full active lives without immunosuppressive medications. 88.9% (n=8) patients have achieved at least marked improvement, with 2 patients achieved complete remission. Till now, the longest follow-up so far is 2.4 years, and only 1 patient suffered from MG recurrence. All the 9 patients had antibodies to AChR. The AchR-Ab levels were decreased, but AchR antibody responses still existed in all patients after docetaxel/cisplatin therapy. Our results indicate that docetaxel/cisplatin therapy could produce marked clinical improvement without complete elimination of the AchR-Ab response. Similar observations have been reported by Daniel et al. They reported that clinical improvement was achieved in patients with refractory myasthenia treated with high-dose cyclophosphamide, without complete elimination of AchR antibody response \[[@j_med-2017-0058_ref_019],[@j_med-2017-0058_ref_020]\].

Nevertheless, docetaxel/cisplatin treatment may have certain adverse effects. Though the adverse effects observed varied with studies, myelosuppression and gastrointestinal reaction were considered to be the major toxicity associated with chemotherapy \[[@j_med-2017-0058_ref_021], [@j_med-2017-0058_ref_022],[@j_med-2017-0058_ref_023]\]. Myelosuppression, nausea, fatigue, and alopecia have been reported to be the most common adverse effects in patients with non-small-cell lung carcinoma treated with cisplatin plus docetaxel \[[@j_med-2017-0058_ref_024]\]. Park et al. reported that grades III/IV neutropenia, grade III leucopenia, diarrhea and nausea were the major side effects in patients with advanced thymic epithelial tumors treated with docetaxel plus cisplatin chemotherapy. Of the 9 patients treated with docetaxel/cisplatin in this report, 1 patient developed Grade II gastrointestinal reaction, and one had pulmonary infection. No obvious side effects were observed in the other 7 patients. Our results infer that docetaxel/cisplatin therapy is generally safe and well tolerated in thymoma-associated MG patients complicated with diabetes and/or hypertension.

To sum up, in thymoma-associated MG patients complicated with hypertension and/or diabetes, who also either did not respond to thymectomy or suffer from MG recurrence postoperatively, docetaxel/cisplatin therapy may produce impressive and potentially long-term benefits with tolerable side effects. Over the long run, docetaxel/cisplatin treatment may avoid additional stress in the control of bodyweight, blood pressure and blood glucose causing by long-term low-dose immunosuppressive treatment. However, the sample size of this study is relative small, which may affect the generalization of our results. Further additional subjects with longer follow up are needed to test the durability of therapeutic benefits with this regimen.
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